Literature DB >> 16690178

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.

Lan Wu1, Zhi-Yong Yang, Ling Xu, Brent Welcher, Sarah Winfrey, Yiming Shao, John R Mascola, Gary J Nabel.   

Abstract

To understand the cross-reactivity of antibodies directed against variable regions of human immunodeficiency virus-1 (HIV-1) envelope (Env), chimeric immunogens were prepared from different clades with modifications in variable regions, and the resulting neutralizing antibody response was evaluated. The V3-specific neutralization activity induced by a clade B immunogen was limited to clade B viruses and was blocked by a clade B V3 peptide, but not by analogous clade A or C V3 peptides. In contrast, the V3 response elicited by a clade C immunogen cross-reacted with sensitive clade B viruses. The V3 region from a clade C virus, when introduced into a clade B sequence, elicited cross-clade activity, which could be reversed by V3 peptides derived from clades A and C. Thus, the anti-V3 antibody response elicited by a clade C immunogen could cross-react with heterologous clade viruses. Additionally, we describe a V1-specific immune response that mediated neutralization limited to the homologous HIV IIIB isolate and may be partially responsible for the commonly observed strain-specific neutralization responses elicited by vaccine immunogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690178     DOI: 10.1016/j.vaccine.2006.03.083

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

2.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

4.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

6.  Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

Authors:  M Gordon Joyce; Masaru Kanekiyo; Ling Xu; Christian Biertümpfel; Jeffrey C Boyington; Stephanie Moquin; Wei Shi; Xueling Wu; Yongping Yang; Zhi-Yong Yang; Baoshan Zhang; Anqi Zheng; Tongqing Zhou; Jiang Zhu; John R Mascola; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

7.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

8.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Effective isotope labeling of proteins in a mammalian expression system.

Authors:  Mallika Sastry; Carole A Bewley; Peter D Kwong
Journal:  Methods Enzymol       Date:  2015-10-23       Impact factor: 1.600

10.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.